Caminomed Sp. z o.o. — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

Caminomed Sp. z o.o.

Location

Tarnowskie Gory, Poland

Identifier

ORG-100052129

Address

Ul. Kardynala Stefana Wyszynskiego 3a, 42-600, Poland

Departments

3605: Ophthalmology
616002: Ophtalmology
Caminomed
n/a
Ophtalmology
Specjalistyczne Gabinety Lekarskie

Clinical trials at this site (9)

Search interface

A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio… Pending

2025-523704-77-00 Geographic atrophy secondary to age-related macular deg 4
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema Recruiting

2025-522231-34-00 Diabetic Macular Edema 5 2026-03-31
A study to test whether BI 1815368 helps people with an eye condition called diabetic macular edema Recruiting

2024-520384-14-00 Centre-involved diabetic macular edema 4 2025-11-20
A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge… Recruiting

2023-509547-27-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2025-05-22
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended

2025-520809-12-00 Diabetic Macular Edema 10 2025-10-16
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration… Ended

2024-515022-88-00 Dry Age-Related Macular Degeneration (AMD) with geograp 5 2025-03-03
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended

2024-510944-30-00 Diabetic Macular Edema 10 2024-11-22
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503669-50-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-12-27
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Neovascular age-related macular degeneration (wet AMD) 5 2021-09-23